CASI Pharmaceuticals, Inc. (CASI) Stock Price Down 6.1%
Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) fell 6.1% during trading on Thursday . The company traded as low as $2.42 and last traded at $2.47. 566,013 shares changed hands during mid-day trading, an increase of 144% from the average session volume of 231,759 shares. The stock had previously closed at $2.63.
A number of brokerages have recently commented on CASI. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. ValuEngine downgraded CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.
CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. analysts predict that CASI Pharmaceuticals, Inc. will post -0.15 EPS for the current fiscal year.
In other CASI Pharmaceuticals news, Director Wei-Wu He purchased 315,327 shares of the stock in a transaction on Friday, September 15th. The shares were bought at an average price of $1.33 per share, for a total transaction of $419,384.91. Following the completion of the transaction, the director now owns 212,323 shares of the company’s stock, valued at approximately $282,389.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired 996,329 shares of company stock worth $1,647,138 in the last quarter. 13.01% of the stock is currently owned by company insiders.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.